Dr. John Gerrard, the Chief Health Officer of Queensland, made an admission that we’ve screamed from the rooftops for months now.
The rise in cardiac-related issues, particularly myocarditis.
Gerrard commented during a press conference:
The Australian Health Official in the video is:
Dr. John Gerrard, the relatively new Chief Health Officer of Queensland:https://t.co/vPWwAXTaPJ
— Michael Schuster (@misch711) March 5, 2022
Trending: Mike Lindell: “It’s Over” — Tells Steve Bannon He Finally Has All The Evidence He’s Been Waiting On!
“It does concern us when there are deaths at home,” Gerrard mentioned. “We’re seeing reports of people having an illness for a short period and then sudden deaths.”
He noted reports of myocarditis elsewhere in Australia and around the world.
“We are certainly keeping a close eye on particularly when there are deaths being investigated,” he reiterated.
Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the lining outside the heart. Since April 2021, increased cases of both have been reported in the U.S. after mRNA Cvd19 vaxx(Pfizer-BioNTech and Moderna), in adolescents and young adults.
THREAD https://t.co/dXeHxds7bP
— TheReal_AnTheFacts©™🇺🇸☦️🇬🇷 (@Real_AnTheFacts) March 5, 2022
In a recently published study, further evidence was presented of vaccine-induced myocarditis in adolescents.
As stated in the European Journal of Clinical Investigation:
Results
Cases of myo/pericarditis (n = 253) included 129 after dose 1 and 124 after dose 2; 86.9% were hospitalized. Incidence per million after dose two in male patients aged 12–15 and 16–17 was 162.2 and 93.0, respectively. Weighing post-vaccination myo/pericarditis against COVID-19 hospitalization during delta, our risk-benefit analysis suggests that among 12–17-year-olds, two-dose vaccination was uniformly favourable only in nonimmune girls with a comorbidity. In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates. In the setting of omicron, one dose may be protective in nonimmune children, but dose two does not appear to confer additional benefit at a population level.
Conclusions
Our findings strongly support individualized paediatric COVID-19 vaccination strategies which weigh protection against severe disease vs. risks of vaccine-associated myo/pericarditis. Research is needed into the nature and implications of this adverse effect as well as immunization strategies which reduce harms in this overall low-risk cohort.
The preprint on vax myocarditis that broke the world: published. 🧵
TL/DR: findings strongly support individualized paediatric COVID-19 vaccination strategies which weigh protection against severe disease vs. risks of vaccine-associated myo/pericarditishttps://t.co/RR3GT1UGe1
— Anish Koka, MD (@anish_koka) March 5, 2022
And given the high inoculation rate, the VAERS reporting system likely underreports the number of myocarditis cases.
3. Matthew Oster, peds cardiologist/VRBPAC presenter : recent JAMA paper on VAERS myocarditis independently asserts that passive reporting in VAERS , high verification rate in their study, suggest VAERS rates are likely an undercount…
https://t.co/2YKFsKjysb— Anish Koka, MD (@anish_koka) March 5, 2022
Despite countless studies noting the concern of vaccine-induced myocarditis, some individuals still deny the validity of this severe adverse reaction.
Yet, this dangerous medical experiment is still available for children as young as five-years-old in many countries.
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!